Madrigal Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 276
- Market Cap
- $5.5B
- Introduction
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.
Biopharma Q1 Updates: New Drug Launches and FDA Extension for Cytokinetics' Aficamten
Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls.
Madrigal's Resmetirom Shows Promise in NASH Treatment Where Others Have Failed
Madrigal Pharmaceuticals' resmetirom demonstrated significant efficacy in the Phase 3 MAESTRO-NASH trial, achieving both primary endpoints of NASH resolution and liver fibrosis improvement.
Inventiva Restructures: Halves Workforce to Focus on Late-Stage MASH Drug Lanifibranor
French biotech Inventiva announces major restructuring, planning to lay off 50% of employees and discontinue all preclinical research except for its lead MASH candidate lanifibranor.
Madrigal's Rezdiffra Shows Promise in MASH Cirrhosis with Two-Year Data
Madrigal Pharmaceuticals reports Rezdiffra (resmetirom) demonstrates potential benefits in patients with compensated MASH cirrhosis (F4c).
Madrigal Pharmaceuticals Initiates FDA Submission for NASH Treatment Resmetirom
Madrigal Pharmaceuticals has begun a rolling submission to the FDA for resmetirom, a potential treatment for NASH with liver fibrosis.
FDA Approvals in 2024: Novel Therapies for MASH, WHIM Syndrome, Pediatric Glioma, MDS, and Bladder Cancer
The FDA approved Madrigal's Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a significant unmet need in liver disease.
FDA Approvals in 2024: NASH Treatment, DMD Therapy, Novel Schizophrenia Drug, and Breast Cancer Advancement
The FDA approved Rezdiffra (resmetirom) as the first specific treatment for nonalcoholic steatohepatitis (NASH), addressing a critical unmet need for patients with liver damage.
Madrigal Pharmaceuticals' Rezdiffra Sees Strong Uptake and Expansion Potential in MASH Treatment
Madrigal Pharmaceuticals' Rezdiffra, the first FDA-approved treatment for MASH, is experiencing rapid sales growth, with over 6,800 patients on treatment in Q3 2024.
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
FDA Approves Rezdiffra (resmetirom) for NASH with Liver Fibrosis
The FDA has granted accelerated approval to Rezdiffra (resmetirom) for treating noncirrhotic NASH with moderate to advanced liver fibrosis.